Healthcare Services Acquisition Corporation Class A Common Stock
HCAR
HCAR was delisted on the 22nd of December, 2022.
0 hedge funds and large institutions have $0 invested in Healthcare Services Acquisition Corporation Class A Common Stock in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 78 closing their positions.
100% less funds holding
Funds holding: 78 → 0 (-78)
100% less capital invested
Capital invested by funds: $304M → $0 (-$304M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 78
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
-$30.5M |
| 2 |
BlackRock
New York
|
-$21M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$16M |
| 4 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
-$15.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$14.2M |
HCAR Hedge Fund Activity: Q4 2022 in Review
0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Healthcare Services Acquisition Corporation Class A Common Stock (HCAR) for Q4 2022, worth a combined $0 — down 100% from $304M a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of HCAR and 0 opened new positions — a net loss of 78 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Glazer Capital LLC, exiting entirely with an estimated $30.5M sold.
- 0 institutional investors held Healthcare Services Acquisition Corporation Class A Common Stock (HCAR) as of Q4 2022, down from 78 in Q3 2022.
- Funds reported $0 of Healthcare Services Acquisition Corporation Class A Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
- 0 funds opened new Healthcare Services Acquisition Corporation Class A Common Stock positions in Q4 2022 and 78 closed out, a net change of -78 holders.
- The largest Healthcare Services Acquisition Corporation Class A Common Stock seller in Q4 2022 was Glazer Capital LLC, an estimated $30.5M sold.
Based on aggregated 13F filings for Q4 2022.